Welcome to our dedicated page for DarioHealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on DarioHealth stock.
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
DarioHealth's holistic approach offers continuous and customized care, disrupting the traditional episodic approach to healthcare. The company empowers people to adapt their lifestyles for sustainable behavior change, driving exceptional satisfaction, retention, and results. Dario's solutions are globally available to health plans, self-insured employers, care providers, and consumers.
One of DarioHealth's latest achievements includes the acquisition of Twill, Inc., a move that nearly doubles its pro forma revenues for 2023 and enhances its ability to deliver comprehensive digital health solutions. The integration of Twill is expected to create immediate scale, boost gross margins to approximately 80-85% by 2025, and accelerate the path to profitability through significant cost synergies.
Recent news highlights include Dario's partnership with Blue Shield of California to make its award-winning digital health platform, Wellvolution, more accessible to Spanish speakers. This initiative aims to close care gaps in underserved communities by offering personalized solutions for hypertension, diabetes, weight management, and mental health support. Additionally, Dario announced a new contract to provide its cardiometabolic solution to a regional union, further expanding its presence in the public and labor sectors.
DarioHealth's clinical research continuously demonstrates the efficacy of its digital solutions. For instance, a recent study published in the Journal of Internet Medicine (JMIR) showed significant reductions in blood glucose levels and BMI for members using Dario's weight monitoring features. Other studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes highlighted the company's ability to deliver improved health outcomes through integrated solutions.
Financially, DarioHealth reported strong performance in Q1 2024, with revenues of $5.8 million driven by growth in its Business-to-Business-to-Consumer (B2B2C) model. The company continues to launch new customer partnerships and expects further revenue growth throughout 2024.
With a strong cash position and ongoing innovation, DarioHealth is well-prepared to execute its strategy and solidify its leadership in the digital health space.
DarioHealth Corp. (Nasdaq: DRIO) announced its Q3 2021 financial results, showcasing a remarkable 176% revenue growth year-over-year, reaching $5.6 million. Pro-forma gross margin improved to 45% from 26.9% a year prior. Despite robust revenue growth, the company reported an operating loss of $22.5 million, up 240.8% from Q3 2020. Dario secured 47 contracts to date, with a billion-dollar pipeline, primarily focused on multi-condition digital health solutions. The firm is well-funded with $51.3 million in cash, supporting its growth strategy in the competitive digital therapeutics market.
DarioHealth Corp. (Nasdaq: DRIO) has appointed Jerrod Helms as Chief Commercial Officer to enhance its growth in employer, payer, and provider markets amid significant commercial acceleration. Mr. Helms, with extensive sales leadership experience in healthcare, joins from Ginger and Headspace. The appointment aims to capitalize on rising demand for Dario's multi-chronic digital therapeutic solutions. The company is optimistic about expanding its market presence and achieving accelerated growth moving into 2022.
DarioHealth Corp. (NASDAQ: DRIO) is set to release its financial results for Q3 2021 on November 15, 2021, after trading. A conference call will occur on November 16, 2021, at 8:30 AM ET. Key executives including CEO Erez Raphael will lead the call.
Investors can dial in using the numbers 877-451-6152 (US) or 201-389-0879 (international). The webcast will be accessible [here](https://viavid.webcasts.com/starthere.jsp?ei=1511170&tp_key=13b2851117). Replays will be available until December 16, 2021.
On November 5, 2021, DarioHealth Corp. (Nasdaq: DRIO) announced its participation in two upcoming investor conferences. The first is the Credit Suisse 30th Annual Healthcare Conference on November 9, featuring a fireside chat with CEO Erez Raphael at 9:40 am EST. The second event is the Craig-Hallum 12th Annual Alpha Select Conference on November 16. Interested parties can access the live and archived webcasts of these events on DarioHealth's investor website. DarioHealth is at the forefront of digital therapeutics, offering comprehensive solutions for chronic condition management.
DarioHealth Corp. (Nasdaq: DRIO) announced a strategic partnership with a national benefits administrative platform to deliver its digital therapeutic solutions, beginning January 2022. This collaboration aims to provide integrated chronic condition management solutions, including diabetes and hypertension, to a broad employer base. Dario's platform focuses on improving health outcomes and lowering costs for users through an AI-driven journey engine, enhancing accessibility in seven languages. This partnership is expected to expand Dario's visibility among employers seeking scalable health solutions.
DarioHealth Corp. (Nasdaq: DRIO) has secured contracts with two regional providers in Hawaii and Georgia for its Remote Patient Monitoring (RPM) services, enhancing its presence in the RPM market. These agreements focus on managing diabetes and hypertension, addressing common chronic conditions. Dario currently supports over 197,000 members on its digital therapeutics platform, showcasing its credibility among providers. The company's innovative platform offers personalized solutions, appealing to healthcare providers seeking effective patient engagement.
DarioHealth has partnered with Virgin Pulse to provide its digital therapeutic solutions to global employers and health plans. This collaboration allows eligible employees to access Dario's services through Virgin Pulse's Homebase for Health® platform. The integrated solutions support various chronic conditions, utilizing AI and extensive user data for personalized health management. Virgin Pulse aims to enhance member health outcomes by simplifying access to Dario's services, which are expected to decrease healthcare costs and improve clinical results.
DarioHealth Corp. (Nasdaq: DRIO) recently launched Dario Move, a new digital physical therapy solution aimed at managing musculoskeletal (MSK) conditions. This innovative product was presented at HLTH 2021 in Boston. The solution integrates advanced sensor technologies to provide personalized exercise programs and real-time coaching, enhancing accessibility to treatment. With 50% of U.S. adults affected by MSK disorders, Dario Move aims to reduce care costs and improve patient engagement. The company highlights the growing need for such digital therapies in an increasingly expensive healthcare landscape.
FAQ
What is the current stock price of DarioHealth (DRIO)?
What is the market cap of DarioHealth (DRIO)?
What is DarioHealth Corp.?
What recent achievements has DarioHealth made?
How does DarioHealth's platform work?
What clinical results support DarioHealth's solutions?
Who are DarioHealth's target customers?
What are the financial prospects for DarioHealth?
What is the significance of DarioHealth's acquisition of Twill?
How does DarioHealth address language barriers in healthcare?
What recent partnerships has DarioHealth announced?
What are the future plans for DarioHealth?
